Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ChAdOx1 nCoV-19 Vaccine · AZD-1222

Vaccine (Adenoviral vector) · Immune activation, directed at SARS-CoV-2 spike protein · developed by Valneva Austria GmbH

Phase 3 Most advanced trial (none active)

VALN Developer

1 Registered trials

What is ChAdOx1 nCoV-19 Vaccine?

ChAdOx1 nCoV-19 (AZD1222) is a replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein. Upon administration it expresses the spike protein, which induces humoral and cell-mediated immune responses against SARS-CoV-2. It is studied for the prevention of SARS-CoV-2 virus infection (COVID-19).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AZD-1222
Drug type: Vaccine (Adenoviral vector)
Targets: SARS-CoV-2 spike protein (antigen)
Mechanism: Immune activation, directed at SARS-CoV-2 spike protein
Pathways: humoral immune response, cell-mediated immune response
Therapy area: Infectious disease
Developer: Valneva Austria GmbH (VALN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: B5S3K2V0G8

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04864561	Phase 3	SARS-CoV-2 Virus Infection	Completed	VALN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

SARS-CoV-2 Virus Infection

More from Valneva Austria GmbH

IC51 FDA approved Japanese encephalitis virus vaccine, inactivated FDA approved 3M-052-AF Phase 1 IC41 Phase 2 IC43 Phase 2/3 IC47 Phase 1 IC84 Phase 1 ISS 1018 CpG Oligodeoxynucleotide Phase 1 JE-VAX Phase 3 Pneumococcal 7-Valent Conjugate Vaccine Phase 3 VLA1553 Phase 3 VLA1601 Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the VALN page.

Follow VALN, the company behind ChAdOx1 nCoV-19 Vaccine

See VALN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VALN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z